Skip to main content
. Author manuscript; available in PMC: 2017 Oct 20.
Published in final edited form as: Thromb Haemost. 2010 Sep 30;105(1):21–30. doi: 10.1160/TH10-07-0446

Figure 5. The CUB-1 cysteine mutants maintained VWF-cleaving activity.

Figure 5

(A) Recombinant WT ADAMTS-13 and its mutants (5 μg/ml each) were first activated by barium and then incubated with plasma VWF (5 μg) for 1 – 24 hrs and tested for their (UL)VWF cleaving activity in the presence of urea. The reaction mix was then separated on 7% SDS-PAGE and immunoblotted with a polyclonal VWF antibody. Because the consensus mutants had similar activity, only C1213S was showed in Panel A. (B) Summary of the VWF-cleaving activity of WT ADAMTS-13 and cysteine mutants. ADAMTS-13 was absent in the control experiments (n = 5). (C) C1275S was tested for cleaving pVWF multimers under static conditions before and after four weeks of storage (need add the molecular weight marker and time points.).